Skip to content

Addiction research published in 2016

Page 2 of 2: studies 21 to 33 of 33, newest first. Back to the addiction overview

Studies

The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations

International Journal of Drug Policy March 23, 2016 Christophe Soussan, Anette Kjellgren 152 citations

BACKGROUND: The increasing number of Novel Psychoactive Substances (NPS) constitutes a challenge for public health agencies and researchers worldwide. Scientific studies about NPS and their users are limited and there is a need to explore the general motivations for NPS use but also to examine if and how the motivations differ between substances from separate effect classes. The aim of the...

Salvia divinorum: An overview of the usage, misuse, and addiction processes.

Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists March 1, 2016 Rathi Mahendran, Haikel A Lim, Joyce Y S Tan et al.

Salvia divinorum, a sage plant with leaves that can produce a psychoactive high, has been used for hundreds of years for its psycho-mimetic effects in religious rituals in South America. Salvia has now become popular mainly with adolescents and young adults for the short-lived relatively pleasant experiences many consider a "legal high" and its ready availability through Internet purchases. The...

Treatment of heroin dependence with ibogaine

European Psychiatry March 1, 2016 Arnt Schellekens, Toon Van Oosteren, Thomas Knuijver et al. 1 citation

Background The use of the hallucinogen ibogaine as an anti-addiction agent has been described in several case reports, dating back to the eighties. The anti-addiction properties of ibogaine have been confirmed in a large body of animal work. Ibogaine has been shown to be effective in reducing withdrawal severity and substance use for a variety of substances, including cocaine and opiates....

DOI: 10.1016/j.eurpsy.2016.01.799 (opens in new tab) Opiate Pharmacology Hallucinogen Heroin +1

Deconstructing the Iboga Alkaloid Skeleton: Potentiation of FGF2-induced Glial Cell Line-Derived Neurotrophic Factor Release by a Novel Compound.

ACS Chemical Biology January 15, 2016 Madalee M Gassaway, Teresa L Jacques, Andrew C Kruegel et al. 23 citations

Modulation of growth factor signaling pathways in the brain represents a new experimental approach to treating neuropsychiatric disorders such as depression, anxiety, and addiction. Neurotrophins and growth factors exert synaptic, neuronal, and circuit level effects on a wide temporal range, which suggests a possibility of rapid and lasting therapeutic effects. Consequently, identification of...

DOI: 10.1021/acschembio.5b00678 (opens in new tab) Full text (opens in new tab) Addiction Neuroprotection Brain protection Neurological protection +22

Classic hallucinogens in the treatment of addictions.

Progress in Neuro-Psychopharmacology and Biological Psychiatry January 4, 2016 Michael P. Bogenschutz, Matthew W Johnson

Addictive disorders are very common and have devastating individual and social consequences. Currently available treatment is moderately effective at best. After many years of neglect, there is renewed interest in potential clinical uses for classic hallucinogens in the treatment of addictions and other behavioral health conditions. In this paper we provide a comprehensive review of both...

Perceptions of an Adapted Mindfulness Program for Persons Experiencing Substance Use Disorders and Traumatic Brain Injury.

Journal of Addictions Nursing 2016 Gisli K Kristofersson, Tom Beckers, Rick Krueger

Of the 1.4 million Americans who sustain traumatic brain injuries (TBIs) each year up to half experience substance use disorders (SUDs). This often leads to various issues such as increased rates of mental health problems and delay or lack of return to full employment. The purpose of this program evaluation was to describe Vinland National Center's (Vinland's) client and staff perceptions of a...

[Drug Dependence and Cytotoxicity of Law-evading Drugs: Their Identities Explored from Basic Research].

Yakugaku Zasshi 2016 Masahiko Funada

Cases of people experiencing disturbed consciousness or dyspnea, causing traffic accidents, or requiring ambulance transport to hospital due to abuse of law-evading chemical substances have become a serious social problem in Japan. Most law-evading herbal products are marketed as incense or herbs and consist of finely chopped, dry vegetative matter mixed with chemical substances (drugs)....

Effect of Mindfulness Meditation on the Quality of Life of Alcoholics in a Selected De-addiction Centre at Mangalore, Karnataka

2016 Beena Antony, Agnes Elizabeth Jose

The aim of the study was to determine the effect of Mindfulness Meditation on the Quality of Life (QOL) of alcoholics. A quantitative experimental evaluative approach was adapted and pre-experimental research design (one group pre-test – post-test design) was used. The sample consisting of 30 alcoholics in the selected de-addiction centre chosen by purposive sampling technique. Tools used were...

DOI: 10.48029/nji.2016.cvii508 (opens in new tab) Meditation Addiction Clinical psychology Analysis of variance +5

Psychiatric comorbidities in a young man with subacute myelopathy induced by abusive nitrous oxide consumption: a case report.

Substance Abuse and Rehabilitation 2016 Falk Mancke, Gintarė Kaklauskaitė, Jennifer Kollmer et al.

Nitrous oxide (N2O), a long-standing anesthetic, is known for its recreational use, and its consumption is on the rise. Several case studies have reported neurological and psychiatric complications of N2O use. To date, however, there has not been a study using standardized diagnostic procedures to assess psychiatric comorbidities in a patient consuming N2O. Here, we report about a 35-year-old...

DOI: 10.2147/sar.s114404 (opens in new tab) Full text (opens in new tab) Substance use disorder Addictive disorders Laughing gas Subacute combined degeneration +1

Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics.

International review of neurobiology 2016 L F Tófoli, D B De Araujo 25 citations

Despite reports of apparent benefits, social and political pressure beginning in the late 1960s effectively banned scientific inquiry into psychedelic substances. Covert examination of psychedelics persisted through the 1990s; the turn of the century and especially the past 10 years, however, has seen a resurgent interest in psychedelic substances (eg, LSD, ayahuasca, psilocybin). This chapter...

DOI: 10.1016/bs.irn.2016.06.005 (opens in new tab) Full text (opens in new tab) Electroencephalography Neuroimaging Psychedelic agents Substance-related disorders +1

The Legal Highs of Novel Drugs of Abuse

Journal of Drug Abuse 2016 Pierluigi Pompei 4 citations

Abstract The abuse of drugs is a widespread and growing issue, both in United States and Europe, as a number of synthetic drugs have raised popularity over the past years for recreational use. Moreover, the nature of addiction is often debated as either a lifestyle choice that may underline a physiological vulnerability, or a chronic brain disease with remarkable epigenetic, neurodevelopmental...

DOI: 10.21767/2471-853x.100025 (opens in new tab) Full text (opens in new tab) Addiction Synthetic cannabinoids Recreational drug Drugs of abuse +1

Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.

Journal of Psychoactive Drugs 2016 Laurie Cloutier-Gill, Evan Wood, Trevor Millar et al. 22 citations

Opioid use disorders (OUD) translate into major health, social, and economic consequences. Opioid agonist medications, which generally require long-term administration, are the mainstay pharmacological treatment of OUD. However, a large proportion of individuals with OUD either refuse or fail to respond to these therapies. Ibogaine, a naturally occurring substance found in the Tabernanthe iboga...

DOI: 10.1080/02791072.2016.1180467 (opens in new tab) Full text (opens in new tab) Methadone maintance therapy Opioid agonist treatment Opioid use disorders Ibogaine treatment +7

Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats.

Pharmacology, Biochemistry, and Behavior 2016 Amir H Rezvani, Marty C Cauley, Susan Slade et al. 22 citations

The ibogaine derivative 18-methoxycoronaridine (18-MC) has been found to decrease self-administration of morphine, nicotine and alcohol in rats after systemic injection. However oral dosing is the preferred route clinically. The current study evaluated the effect of oral 18-MC dosing in rats on alcohol and nicotine self-administration. For the nicotine study, young adult female Sprague-Dawley...

DOI: 10.1016/j.pbb.2016.10.010 (opens in new tab) Full text (opens in new tab) Alcohol preferring rat Drinking Addiction treatment Alcoholism research +2